ZA201100426B - Crystalline forms of a pyridine derivative - Google Patents

Crystalline forms of a pyridine derivative

Info

Publication number
ZA201100426B
ZA201100426B ZA2011/00426A ZA201100426A ZA201100426B ZA 201100426 B ZA201100426 B ZA 201100426B ZA 2011/00426 A ZA2011/00426 A ZA 2011/00426A ZA 201100426 A ZA201100426 A ZA 201100426A ZA 201100426 B ZA201100426 B ZA 201100426B
Authority
ZA
South Africa
Prior art keywords
crystalline forms
pyridine derivative
pyridine
derivative
crystalline
Prior art date
Application number
ZA2011/00426A
Other languages
English (en)
Inventor
David Clapham
Ronnie Maxwell Lawrence
Clare Louise Anderton
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of ZA201100426B publication Critical patent/ZA201100426B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA2011/00426A 2008-08-05 2011-01-17 Crystalline forms of a pyridine derivative ZA201100426B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0814340.6A GB0814340D0 (en) 2008-08-05 2008-08-05 Anhydrous crystol form fo a pyridine derivative
PCT/EP2009/060089 WO2010015626A1 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
ZA201100426B true ZA201100426B (en) 2012-03-28

Family

ID=39767571

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/00426A ZA201100426B (en) 2008-08-05 2011-01-17 Crystalline forms of a pyridine derivative

Country Status (14)

Country Link
US (1) US8093242B2 (OSRAM)
EP (1) EP2321324A1 (OSRAM)
JP (1) JP2011529942A (OSRAM)
KR (1) KR20110052686A (OSRAM)
CN (1) CN102171219A (OSRAM)
AU (1) AU2009279135B2 (OSRAM)
BR (1) BRPI0917224A2 (OSRAM)
CA (1) CA2733235A1 (OSRAM)
EA (1) EA201170300A1 (OSRAM)
GB (1) GB0814340D0 (OSRAM)
IL (1) IL210777A0 (OSRAM)
MX (1) MX2011001414A (OSRAM)
WO (1) WO2010015626A1 (OSRAM)
ZA (1) ZA201100426B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2772168C (en) 2009-08-27 2019-01-08 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative
CN114272242A (zh) * 2015-05-18 2022-04-05 康堤医疗有限公司 用于治疗性激素依赖性疾病的双重nk-1/nk-3受体拮抗剂
CA3092238A1 (en) 2018-03-14 2019-09-19 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
WO2021094247A1 (en) 2019-11-15 2021-05-20 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69728883T2 (de) 1996-07-17 2005-04-07 Merck & Co., Inc. Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
DK1035115T3 (da) 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
WO2001030348A1 (en) 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
CN1852712B (zh) 2003-07-03 2010-06-09 弗·哈夫曼-拉罗切有限公司 用于治疗精神分裂症的双重nk1/nk3拮抗剂
JO2722B1 (en) * 2005-09-09 2013-09-15 سميث كلاين بيتشام كوربوريشن New vehicles

Also Published As

Publication number Publication date
AU2009279135A1 (en) 2010-02-11
EA201170300A1 (ru) 2011-08-30
CA2733235A1 (en) 2010-02-11
GB0814340D0 (en) 2008-09-10
US8093242B2 (en) 2012-01-10
MX2011001414A (es) 2011-04-04
JP2011529942A (ja) 2011-12-15
US20110136798A1 (en) 2011-06-09
BRPI0917224A2 (pt) 2015-11-24
AU2009279135B2 (en) 2012-09-13
EP2321324A1 (en) 2011-05-18
WO2010015626A1 (en) 2010-02-11
IL210777A0 (en) 2011-03-31
KR20110052686A (ko) 2011-05-18
CN102171219A (zh) 2011-08-31

Similar Documents

Publication Publication Date Title
LT2155200T (lt) Karbamoil-cikloheksano darinio kristalinė forma
ZA201105479B (en) Pyridine derivative
IL209196A0 (en) A crystalline form of posaconazole
GB0819182D0 (en) Crystalline forms
SG10201500451TA (en) Crystalline forms of a purine derivative
IL212536A0 (en) Substituted pyridines having a herbicidal effect
EP2412708A4 (en) SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
EP2514747A4 (en) SUBSTITUTED AMINOTHIAZINE DERIVATIVE
IL214126A0 (en) Crystalline insulin-conjugates
IL206276A0 (en) Pyridine derivatives
IL209727A0 (en) Pyridine compounds
ZA201200812B (en) Anhydrate forms of a pyridine derivative
IL213466A0 (en) Spiroindolinone pyridine derivative
ZA201105045B (en) Crystalline forms of genistein
SI2358676T1 (sl) Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
IL210777A0 (en) Crystalline forms of a pyridine derivative
GB0902406D0 (en) Crystalline polymorphic form
SI2303866T1 (sl) Kristalne oblike natrijevega rabeprazolata
IL207315A0 (en) Piperidine derivative
IL214028A0 (en) A novel cyanopyrimidine derivative
EP2285778A4 (en) NIKOTINAMIDDERIVATE
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
IL195092A0 (en) Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate
GB0812895D0 (en) Crystalline carbohydrate derivative
HU0800755D0 (en) Novel crystalline forms